XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary
Alberta
T2P 4K9
Canada
Tel: 1-403-455-7727
Website: http://www.xortx.com/
Email: info@xortx.com
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.
LEADERSHIP:
CEO: Allen Davidoff
CLINICAL TRIAL:
118 articles about XORTX Therapeutics Inc.
-
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
-
XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study
8/22/2022
XORTX Therapeutics Inc. is pleased to announce positive topline results from its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2– (“Part 2”) showing a substantial increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with food compared to the fasted state.
-
Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.
-
XORTX Announces Submission to European Medicines AgencyScientific Advice from EMA Committee for Medicinal Products for Human Use Requested
7/19/2022
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a request for “scientific advice review” to the European Medicines Agency (the “EMA”) and more specifically the Committee for Medicinal Products for Human Use (the “CHMP”) regarding the XRx-008 program.
-
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical TrialClinical Trial Shows Substantially Improved Bioavailiability
7/13/2022
XORTX Therapeutics Inc. is pleased to announce positive topline results from Part 1 of the three part Pharmacokinetics Bridging Study – XRX-OXY-101 (“PK Clinical Trial”) - showing a substantial increase in oral bioavailability of two versions of XORTX’s proprietary oxypurinol formulation compared to a control formulation.
-
XORTX Announces “Fireside Chat” with XORTX CEO
6/21/2022
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that on June 22, 2022 at 11am EST, Dr. Allen Davidoff, XORTX’s CEO, will host a “Fireside Chat” that will include a presentation “Exciting Developments in New Therapies for Progressive Kidney Diseases”.
-
XORTX to Present at BIO International Convention 2022
6/13/2022
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2022, being held June 13th through 16th, 2022.
-
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
-
XORTX to Present at LD Micro Invitational 2022
6/8/2022
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the LD Micro Invitational 2022, being held June 7th through 9th, 2022.
-
XORTX Welcomes New Member to the Board of Directors and Appoints Chair
6/6/2022
XORTX Therapeutics Inc. is pleased to welcome and appoint Mr. Anthony Giovinazzo to the Board of Directors and as Chair of the Board.
-
XORTX to Present at H. C. Wainwright Global Investment Conference 2022
5/25/2022
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H. C. Wainwright Global Investment Conference 2022, a hybrid in-person/ virtual conference being held May 23rd through 26th , 2022.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease
5/5/2022
XORTX Therapeutics Inc. is pleased to announce that the Company has received official notification from the US Food and Drug Association that the Company’s recent IND application has been reviewed and cleared.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical TrialBridging Pharmacokinetics Study Part 1 Recruitment Completed for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease
5/3/2022
XORTX Therapeutics Inc. is pleased to announce that dosing of human subjects has been initiated in the XRX-OXY-101 bridging pharmacokinetics study (“PK Study”).
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
XORTX Receives Small and Medium Enterprise Status for the European Union
4/20/2022
XORTX Therapeutics Inc., a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of Small and Medium Enterprise status for the European Union.
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
XORTX Receives No Objection Letter from Health Canada
4/12/2022
XORTX Therapeutics Inc., a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of a no objection letter from Health Canada regarding the Company’s upcoming XRX-OXY-101 clinical bridging pharmacokinetics study.
-
XORTX Announces Grant of US Patent
4/7/2022
XORTX Therapeutics Inc. is pleased to announce receipt of notification that the patent “Formulations of Xanthine Oxidase Inhibitors” will be granted by the United States Patent Office (USPTO).